	US 12,246,048 B2
	Recombinant herpes simplex virus having modified glycoprotein gH for retargeting and use thereof
Heechung Kwon, Gyeonggi-do (KR); and Hyunjung Baek, Gyeonggi-do (KR)
Assigned to Gencellmed Inc., Seoul (KR)
Appl. No. 17/430,018
Filed by Gencellmed Inc., Seoul (KR)
PCT Filed Feb. 19, 2021, PCT No. PCT/KR2021/002154 § 371(c)(1), (2) Date Aug. 11, 2021, PCT Pub. No. WO2021/251588, PCT Pub. Date Dec. 16, 2021.
Claims priority of application No. 10-2020-0071873 (KR), filed on Jun. 12, 2020; and application No. 10-2020-0072979 (KR), filed on Jun. 16, 2020.
Prior Publication US 2022/0305067 A1, Sep. 29, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/763 (2015.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 16/32 (2006.01); C12N 7/00 (2006.01)

CPC A61K 35/763 (2013.01) [A61P 29/00 (2018.01); A61P 35/00 (2018.01); C07K 14/705 (2013.01); C07K 16/32 (2013.01); C12N 7/00 (2013.01)]

18 Claims

1. A recombinant herpes simplex virus, configured such that a cell-targeting domain, which specifically recognizes and binds to a target molecule of a target cell, is inserted and fused into a glycoprotein gH,

wherein the cell-targeting domain is inserted and fused into a position between the region of amino acids 29 and 30 in the amino acid sequence of the gH glycoprotein comprising SEQ ID NO: 1.